Literature DB >> 10993276

Macrophages and their subpopulations following allogenic bone marrow transplantation for chronic myeloid leukaemia.

J Thiele1, H M Kvasnicka, D W Beelen, P Wenzel, M L Koepke, L D Leder, U W Schaefer.   

Abstract

A morphometric and immunohistochemical study was performed on 354 bone marrow trephine biopsies derived from 126 patients with chronic myeloid leukaemia (CML) before and after allogeneic bone marrow transplantation (BMT). The purpose of this investigation was to evaluate the macrophage population, including several subsets and their dynamics in the posttransplant period. In addition to the total CD68+ resident (mature) macrophages the so-called activated fraction identified by its capacity to express alpha-D-galactosyl residues, the pseudo-Gaucher cells (PGCs) and the iron-laden histiocytic reticular cells were also considered. Following immuno- and lectin-histochemical staining morphometric analysis was carried out on sequential postgraft bone marrow specimens at standardized intervals. Compared to the normal bone marrow and calculated per haematopoiesis (cellularity) an overall decrease of about 40-50% in the quantity of CD68+ macrophages and the BSA-I+ subpopulation was detectable in the early posttransplant period (9-45 days after BMT). Noteworthy was the temporal recurrence of PGCs in the engrafted bone marrow, which was not associated with a clonally transformed cell population or leukaemic relapse. Reappearance of postgraft PGCs was most prominent in the first 2 months after BMT. This conspicuous feature was presumed to be functionally associated with a pronounced degradation of cell debris following pretransplant myelo-ablative therapy (scavenger macrophages). Evidence for an activation of the BSA-I+ macrophage subset was derived from the identical carbohydrate-binding capacity shown by the PGCs. In the regenerating haematopoiesis shortly after BMT a significant correlation between the number of BSA-I+ macrophages and erythroid precursor cells was determinable. This result implicates a close functional relationship between postgraft reconstitution of erythropoietic islets and centrally localized activated macrophages. In conclusion, findings emerging from this study included the reappearance of PCGs in the engrafted bone marrow independently of a leukaemic relapse and the significant association of the activated BSA-I+ macrophage subset with the recovery of erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993276     DOI: 10.1007/s004280000224

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  5 in total

Review 1.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML.

Authors:  Jian-Xin Song; Zi-Jin Dian; Yan Wen; Fen Mei; Rui-Wei Li; Ya-Lian Sa
Journal:  Biomed Res Int       Date:  2016-11-24       Impact factor: 3.411

3.  Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model.

Authors:  A Thies; P Dautel; A Meyer; U Pfüller; U Schumacher
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

4.  CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stress.

Authors:  Andrew Chow; Matthew Huggins; Jalal Ahmed; Daigo Hashimoto; Daniel Lucas; Yuya Kunisaki; Sandra Pinho; Marylene Leboeuf; Clara Noizat; Nico van Rooijen; Masato Tanaka; Zhizhuang Joe Zhao; Aviv Bergman; Miriam Merad; Paul S Frenette
Journal:  Nat Med       Date:  2013-03-17       Impact factor: 53.440

5.  Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions.

Authors:  Satoshi Nishiwaki; Takayuki Nakayama; Makoto Murata; Tetsuya Nishida; Seitaro Terakura; Shigeki Saito; Tomonori Kato; Hiroki Mizuno; Nobuhiko Imahashi; Aika Seto; Yukiyasu Ozawa; Koichi Miyamura; Masafumi Ito; Kyosuke Takeshita; Hidefumi Kato; Shinya Toyokuni; Keisuke Nagao; Ryuzo Ueda; Tomoki Naoe
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.